NCT06738797View on ClinicalTrials.gov

Association Between the SPHERTEST in Vitro Test and Response to Checkpoint Inhibitor Treatments in Patients With Advanced or Metastatic Urothelial Carcinoma

RecruitingOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Urogenital Neoplasms
Interventions
DIAGNOSTIC_TEST

SPHERTEST test

The SPHERETEST is an in vitro model of heterotypic spheroids composed of commercial urothelial carcinoma tumor cells and leukocyte mononuclear cells from healthy donors.

Trial Locations (5)

Unknown

NOT_YET_RECRUITING

Institut du Cancer de Montpellier, Montpellier

NOT_YET_RECRUITING

Institut Régional du Cancer de Montpellier, Montpellier

NOT_YET_RECRUITING

Centre Antoine Lacassagne, Nice

RECRUITING

CHU de Nimes, Nîmes

RECRUITING

Iuct Oncopole, Toulouse

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nīmes

OTHER